- Home
- CTXR vs FABC Comparison
CTXR vs FABC Comparison
Compare CTXR & FABC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTXR | FABC |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 16.6M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | CTXR | FABC |
|---|---|---|
| Price | $0.57 | $3.35 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 243.2K | ★ 539.6K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.38 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $147.57 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.48 | $2.81 |
| 52 Week High | $2.24 | $4.57 |
Technical Indicators
Market Signals| Indicator | CTXR | FABC |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 44.02 |
| Support Level | $0.55 | $2.81 |
| Resistance Level | $0.60 | $4.57 |
| Average True Range (ATR) | 0.04 | 0.55 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 53.66 | 26.14 |
Price Performance
Historical ComparisonAbout CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.